ondansetron has been researched along with Glioma in 9 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists." | 9.34 | Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020) |
| " K(+)-flux response mechanisms to the antiemetics ondansetron and granisetron were therefore correlated to malignant glioma cell (Mg251) volume response to estramustine phosphate (EMP) in vitro." | 7.71 | Ondansetron but not granisetron affect cell volume regulation and potassium ion transport of glioma cells treated with estramustine phosphate. ( Behnam-Motlagh, P; Grankvist, K; Henriksson, R; Sandström, PE, 2002) |
| "A technique of microscopy with computerised detection of early morphological changes during continuous perifusion was used to monitor the geometry changes of cultured glioma cells (MG-251) when exposed to 40 mg/L estramustine phosphate (EMP) alone or in combination with granisetron (0." | 7.70 | Serotoninergic modulation of cell volume response to estramustine: an image-analysis study on perifused individual glioma cells. ( Behnam-Motlagh, P; Engström, KG; Grankvist, K; Henriksson, R, 1999) |
| "The pharmacological characteristics of 5-HT3 receptor (5-hydroxytryptamine3 receptor) recognition sites labelled with [3H]-(S)-zacopride and [3H]granisetron in membranes prepared from NG108-15 neuroblastoma-glioma cells were directly compared to investigate further differences in the binding characteristics of these two radioligands." | 7.68 | Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron. ( Barnes, JM; Barnes, NM, 1993) |
| "CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists." | 5.34 | Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020) |
| " K(+)-flux response mechanisms to the antiemetics ondansetron and granisetron were therefore correlated to malignant glioma cell (Mg251) volume response to estramustine phosphate (EMP) in vitro." | 3.71 | Ondansetron but not granisetron affect cell volume regulation and potassium ion transport of glioma cells treated with estramustine phosphate. ( Behnam-Motlagh, P; Grankvist, K; Henriksson, R; Sandström, PE, 2002) |
| "A technique of microscopy with computerised detection of early morphological changes during continuous perifusion was used to monitor the geometry changes of cultured glioma cells (MG-251) when exposed to 40 mg/L estramustine phosphate (EMP) alone or in combination with granisetron (0." | 3.70 | Serotoninergic modulation of cell volume response to estramustine: an image-analysis study on perifused individual glioma cells. ( Behnam-Motlagh, P; Engström, KG; Grankvist, K; Henriksson, R, 1999) |
| "The pharmacological characteristics of 5-HT3 receptor (5-hydroxytryptamine3 receptor) recognition sites labelled with [3H]-(S)-zacopride and [3H]granisetron in membranes prepared from NG108-15 neuroblastoma-glioma cells were directly compared to investigate further differences in the binding characteristics of these two radioligands." | 3.68 | Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron. ( Barnes, JM; Barnes, NM, 1993) |
| "The effect of a novel 5-HT3 receptor antagonist, BRL 46470, has been studied on two electrophysiological models for 5-HT3 receptors: grease-gap recordings from rat isolated vagus nerve and whole-cell patch-clamp recordings from mouse neuroblastoma-rat glioma NG108-15 cells." | 3.68 | BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors. ( Blackburn, TP; Grahame-Smith, DG; Leslie, RA; Newberry, NR; Sprosen, TS; Watkins, CJ, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Rosen, T | 1 |
| Seeger, TF | 1 |
| McLean, S | 1 |
| Nagel, AA | 1 |
| Ives, JL | 1 |
| Guarino, KJ | 1 |
| Bryce, D | 1 |
| Furman, J | 1 |
| Roth, RW | 1 |
| Chalabi, PM | 1 |
| Patel, MP | 2 |
| Woodring, S | 1 |
| Randazzo, DM | 1 |
| Friedman, HS | 1 |
| Desjardins, A | 1 |
| Healy, P | 1 |
| Herndon, JE | 2 |
| McSherry, F | 1 |
| Lipp, ES | 1 |
| Miller, E | 1 |
| Peters, KB | 1 |
| Affronti, ML | 2 |
| Morio, K | 1 |
| Watanabe, J | 1 |
| Tsujimoto, Y | 1 |
| Behnam-Motlagh, P | 2 |
| Sandström, PE | 1 |
| Henriksson, R | 2 |
| Grankvist, K | 2 |
| Kidd, FJ | 1 |
| Levy, JC | 1 |
| Nielsen, M | 1 |
| Hamon, M | 1 |
| Gozlan, H | 1 |
| Barnes, JM | 1 |
| Barnes, NM | 1 |
| Newberry, NR | 1 |
| Watkins, CJ | 1 |
| Sprosen, TS | 1 |
| Blackburn, TP | 1 |
| Grahame-Smith, DG | 1 |
| Leslie, RA | 1 |
| Engström, KG | 1 |
1 trial available for ondansetron and Glioma
| Article | Year |
|---|---|
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Brain Neoplasms; Female; Glioma; Humans | 2020 |
8 other studies available for ondansetron and Glioma
| Article | Year |
|---|---|
Synthesis, in vitro binding profile, and central nervous system penetrability of the highly potent 5-HT3 receptor antagonist [3H]-4-(2-methoxyphenyl)-2-[4(5)-methyl-5(4)-imidazolylmethyl]thiazole.
Topics: Animals; Blood-Brain Barrier; Brain; Chemical Phenomena; Chemistry; Glioma; Imidazoles; Mice; Molecu | 1990 |
Letter referencing "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting in glioma patients receiving adjuvant temozolomide".
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patien
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Ondansetron but not granisetron affect cell volume regulation and potassium ion transport of glioma cells treated with estramustine phosphate.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Size; Estramustine; Glioma; Granisetron; Hu | 2002 |
Characterisation of the non-5-HT3 high-affinity 'R' binding site for (R)-zacopride in brain and other tissues.
Topics: Aged; Aged, 80 and over; Animals; Benzamides; Binding Sites; Brain; Bridged Bicyclo Compounds; Bridg | 1993 |
Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron.
Topics: Animals; Benzamides; Biguanides; Binding Sites; Binding, Competitive; Bridged Bicyclo Compounds; Bri | 1993 |
BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors.
Topics: Animals; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Electrophysiology; Glio | 1993 |
Serotoninergic modulation of cell volume response to estramustine: an image-analysis study on perifused individual glioma cells.
Topics: Cell Size; Drug Combinations; Drug Interactions; Estramustine; Glioma; Granisetron; Humans; Ondanset | 1999 |